Predictive value of osteocalcin in bone metastatic differentiated thyroid carcinoma

被引：3

作者：

Gao, Yunchao ^{[1
]}

Lu, Hankui ^{[1
]}

Luo, Qiong ^{[1
]}

Wu, Xiaohui ^{[1
]}

Sheng, Shiwei ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Dept Nucl Med, Shanghai Peoples Hosp 6, Shanghai 200233, Peoples R China

来源：

CLINICAL BIOCHEMISTRY | 2010年 / 43卷 / 03期

关键词：

Bone metastasis; Biochemical markers; Thyroid carcinoma; Osteocalcin; CANCER; MARKERS; TURNOVER;

D O I：

10.1016/j.clinbiochem.2009.08.015

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Objectives: To evaluate the diagnostic value of serum osteocalcin in the detection of bone metastases from differentiated thyroid carcinoma (DTC). Design and methods: Serum samples from DTC patients with (DTC BM+, n = 19) or without bone metastases (DTC BM-, n = 19), and matched healthy volunteers (n=30) were tested for serum osteocalcin with electrochemiluminescent immunoassay. Results: Osteocalcin was higher in DTC BM+ than in DTC BM- patients (+35.8%, p=0.002), acting as an independent risk factor for bone metastases (R(2)=0.142, p=0.039). The sensitivity was 78.9% and the specificity was 63.2% at a cut-off value of 11.2 mu g/L. Conclusions: Serial measurements of osteocalcin could be useful in the detection of bone metastases from DTC. (C) 2009 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

引用

页码：291 / 295

页数：5

共 10 条

[1] Variables predicting distant metastases in thyroid cancer [J].

Clark, JR ;

Lai, P ;

Hall, F ;

Borglund, A ;

Eski, S ;

Freeman, JL .

LARYNGOSCOPE, 2005, 115 (04) :661-667

[2] Bone remodeling markers in the detection of bone metastases in prostate cancer [J].

de la Piedra, C ;

Castro-Errecaborde, NA ;

Traba, ML ;

Méndez-Dávila, C ;

García-Moreno, C ;

de Acuña, LR ;

Rodriguez-Molina, J .

CLINICA CHIMICA ACTA, 2003, 331 (1-2) :45-53

[3] Biochemical markers of bone turnover in patients with thyroid dysfunctions and in euthyroid controls: a cross-sectional study [J].

Engler, H ;

Oettli, RE ;

Riesen, WF .

CLINICA CHIMICA ACTA, 1999, 289 (1-2) :159-172

[4] Bone markers and current laboratory assays [J].

Hannon, RA ;

Eastell, R .

CANCER TREATMENT REVIEWS, 2006, 32 :7-14

[5] Bone metastases from differentiated thyroid carcinoma [J].

Muresan, M. M. ;

Olivier, P. ;

Leclere, J. ;

Sirveaux, F. ;

Brunaud, L. ;

Klein, M. ;

Zarnegar, R. ;

Weryha, G. .

[6] Predictive value of osteocalcin and β-CrossLaps in metastatic breast cancer [J].

Salem, Ahmed M. ;

Zohny, Salmir F. ;

El-Wahab, Manal M. Abd ;

Hamdy, Rehab .

CLINICAL BIOCHEMISTRY, 2007, 40 (16-17) :1201-1208

[7]

Scott Anne M, 2009, Radiol Technol, V80, P241

[8] Thyroid carcinoma [J].

Sherman, SI .

LANCET, 2003, 361 (9356) :501-511

[9] Markers of bone turnover in patients with differentiated thyroid cancer with and following withdrawal of thyroxine suppressive therapy [J].

Toivonen, J ;

Tahtela, R ;

Laitinen, K ;

Risteli, J ;

Valimaki, MJ .

EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 138 (06) :667-673

[10] Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer [J].

Vitale, G ;

Fonderico, F ;

Martignetti, A ;

Caraglia, M ;

Ciccarelli, A ;

Nuzzo, V ;

Abbruzzese, A ;

Lupoli, G .

BRITISH JOURNAL OF CANCER, 2001, 84 (12) :1586-1590

← 1 →